📋 Task Queue Dashboard

Produce a comprehensive, investor-grade deep dive research report on **Idorsia**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/idorsia/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/idorsia/idorsia_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Idorsia Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Biomarin**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/biomarin/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/biomarin/biomarin_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Biomarin Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Jazz Pharmaceuticals**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/jazz-pharmaceuticals/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/jazz-pharmaceuticals/jazz_pharmaceuticals_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Jazz Pharmaceuticals Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Alexion (AstraZeneca)**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/alexion/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/alexion/alexion_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Alexion (AstraZeneca) Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Lundbeck**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/lundbeck/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/lundbeck/lundbeck_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Lundbeck Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Insmed**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/insmed/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/insmed/insmed_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Insmed Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Ultragenyx**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/ultragenyx/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/ultragenyx/ultragenyx_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Ultragenyx Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Sobi (Swedish Orphan)**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/sobi/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/sobi/sobi_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Sobi (Swedish Orphan) Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Arvinas**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/arvinas/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/arvinas/arvinas_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Arvinas Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Moderna**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/moderna/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/moderna/moderna_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Moderna Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Viridian Therapeutics**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/viridian-therapeutics/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/viridian-therapeutics/viridian_therapeutics_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Viridian Therapeutics Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Annexon Biosciences**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/annexon-biosciences/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/annexon-biosciences/annexon_biosciences_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Annexon Biosciences Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Ascendis Pharma**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/ascendis-pharma/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/ascendis-pharma/ascendis_pharma_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Ascendis Pharma Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Neurocrine Biosciences**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/neurocrine-biosciences/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/neurocrine-biosciences/neurocrine_biosciences_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Neurocrine Biosciences Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Ionis Pharmaceuticals**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/ionis-pharmaceuticals/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/ionis-pharmaceuticals/ionis_pharmaceuticals_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Ionis Pharmaceuticals Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Argenx**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/argenx/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/argenx/argenx_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Argenx Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Create an Ada Patient Finder suitability analysis for AstraZeneca's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/astrazeneca/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify AstraZeneca's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in AstraZeneca's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - AstraZeneca's investment appetite for this drug - Is AstraZeneca actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does AstraZeneca need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/astrazeneca/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/astrazeneca/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/astrazeneca/astrazeneca_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "AstraZeneca Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Roche's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/roche/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Roche's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Roche's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Roche's investment appetite for this drug - Is Roche actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Roche need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/roche/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/roche/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/roche/roche_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Roche Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Novartis's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/novartis/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Novartis's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Novartis's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Novartis's investment appetite for this drug - Is Novartis actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Novartis need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/novartis/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/novartis/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/novartis/novartis_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Novartis Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Bristol-Myers Squibb's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/bristol-myers-squibb/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Bristol-Myers Squibb's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Bristol-Myers Squibb's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Bristol-Myers Squibb's investment appetite for this drug - Is Bristol-Myers Squibb actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Bristol-Myers Squibb need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/bristol-myers-squibb/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/bristol-myers-squibb/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/bristol-myers-squibb/bristol_myers_squibb_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Bristol-Myers Squibb Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Sanofi's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/sanofi/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Sanofi's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Sanofi's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Sanofi's investment appetite for this drug - Is Sanofi actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Sanofi need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/sanofi/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/sanofi/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/sanofi/sanofi_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Sanofi Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for GSK's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/gsk/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify GSK's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in GSK's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - GSK's investment appetite for this drug - Is GSK actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does GSK need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/gsk/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/gsk/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/gsk/gsk_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "GSK Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Amgen's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/amgen/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Amgen's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Amgen's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Amgen's investment appetite for this drug - Is Amgen actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Amgen need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/amgen/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/amgen/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/amgen/amgen_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Amgen Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Gilead Sciences's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/gilead-sciences/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Gilead Sciences's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Gilead Sciences's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Gilead Sciences's investment appetite for this drug - Is Gilead Sciences actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Gilead Sciences need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/gilead-sciences/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/gilead-sciences/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/gilead-sciences/gilead_sciences_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Gilead Sciences Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Takeda's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/takeda/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Takeda's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Takeda's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Takeda's investment appetite for this drug - Is Takeda actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Takeda need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/takeda/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/takeda/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/takeda/takeda_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Takeda Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Boehringer Ingelheim's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/boehringer-ingelheim/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Boehringer Ingelheim's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Boehringer Ingelheim's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Boehringer Ingelheim's investment appetite for this drug - Is Boehringer Ingelheim actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Boehringer Ingelheim need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/boehringer-ingelheim/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/boehringer-ingelheim/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/boehringer-ingelheim/boehringer_ingelheim_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Boehringer Ingelheim Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Regeneron's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/regeneron/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Regeneron's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Regeneron's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Regeneron's investment appetite for this drug - Is Regeneron actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Regeneron need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/regeneron/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/regeneron/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/regeneron/regeneron_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Regeneron Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Bayer's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/bayer/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Bayer's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Bayer's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Bayer's investment appetite for this drug - Is Bayer actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Bayer need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/bayer/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/bayer/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/bayer/bayer_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Bayer Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Teva's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/teva/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Teva's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Teva's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Teva's investment appetite for this drug - Is Teva actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Teva need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/teva/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/teva/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/teva/teva_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Teva Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Vertex Pharmaceuticals's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/vertex-pharmaceuticals/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Vertex Pharmaceuticals's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Vertex Pharmaceuticals's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Vertex Pharmaceuticals's investment appetite for this drug - Is Vertex Pharmaceuticals actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Vertex Pharmaceuticals need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/vertex-pharmaceuticals/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/vertex-pharmaceuticals/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/vertex-pharmaceuticals/vertex_pharmaceuticals_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Vertex Pharmaceuticals Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Biogen's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/biogen/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Biogen's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Biogen's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Biogen's investment appetite for this drug - Is Biogen actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Biogen need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/biogen/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/biogen/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/biogen/biogen_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Biogen Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Astellas Pharma's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/astellas-pharma/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Astellas Pharma's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Astellas Pharma's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Astellas Pharma's investment appetite for this drug - Is Astellas Pharma actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Astellas Pharma need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/astellas-pharma/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/astellas-pharma/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/astellas-pharma/astellas_pharma_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Astellas Pharma Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Otsuka's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/otsuka/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Otsuka's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Otsuka's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Otsuka's investment appetite for this drug - Is Otsuka actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Otsuka need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/otsuka/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/otsuka/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/otsuka/otsuka_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Otsuka Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for BridgeBio Pharma's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/bridgebio-pharma/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify BridgeBio Pharma's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in BridgeBio Pharma's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - BridgeBio Pharma's investment appetite for this drug - Is BridgeBio Pharma actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does BridgeBio Pharma need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/bridgebio-pharma/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/bridgebio-pharma/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/bridgebio-pharma/bridgebio_pharma_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "BridgeBio Pharma Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Alnylam Pharmaceuticals's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/alnylam-pharmaceuticals/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Alnylam Pharmaceuticals's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Alnylam Pharmaceuticals's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Alnylam Pharmaceuticals's investment appetite for this drug - Is Alnylam Pharmaceuticals actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Alnylam Pharmaceuticals need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/alnylam-pharmaceuticals/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/alnylam-pharmaceuticals/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/alnylam-pharmaceuticals/alnylam_pharmaceuticals_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Alnylam Pharmaceuticals Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Daiichi Sankyo's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/daiichi-sankyo/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Daiichi Sankyo's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Daiichi Sankyo's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Daiichi Sankyo's investment appetite for this drug - Is Daiichi Sankyo actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Daiichi Sankyo need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/daiichi-sankyo/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/daiichi-sankyo/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/daiichi-sankyo/daiichi_sankyo_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Daiichi Sankyo Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for UCB's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/ucb/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify UCB's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in UCB's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - UCB's investment appetite for this drug - Is UCB actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does UCB need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/ucb/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/ucb/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/ucb/ucb_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "UCB Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Ipsen's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/ipsen/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Ipsen's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Ipsen's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Ipsen's investment appetite for this drug - Is Ipsen actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Ipsen need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/ipsen/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/ipsen/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/ipsen/ipsen_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Ipsen Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Cytokinetics's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/cytokinetics/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Cytokinetics's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Cytokinetics's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Cytokinetics's investment appetite for this drug - Is Cytokinetics actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Cytokinetics need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/cytokinetics/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/cytokinetics/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/cytokinetics/cytokinetics_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Cytokinetics Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Merck KGaA's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/merck-kgaa/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Merck KGaA's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Merck KGaA's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Merck KGaA's investment appetite for this drug - Is Merck KGaA actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Merck KGaA need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/merck-kgaa/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/merck-kgaa/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/merck-kgaa/merck_kgaa_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Merck KGaA Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Galderma's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/galderma/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Galderma's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Galderma's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Galderma's investment appetite for this drug - Is Galderma actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Galderma need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/galderma/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/galderma/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/galderma/galderma_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Galderma Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Esteve's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/esteve/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Esteve's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Esteve's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Esteve's investment appetite for this drug - Is Esteve actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Esteve need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/esteve/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/esteve/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/esteve/esteve_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Esteve Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Tarsus Pharmaceuticals's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/tarsus-pharmaceuticals/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Tarsus Pharmaceuticals's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Tarsus Pharmaceuticals's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Tarsus Pharmaceuticals's investment appetite for this drug - Is Tarsus Pharmaceuticals actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Tarsus Pharmaceuticals need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/tarsus-pharmaceuticals/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/tarsus-pharmaceuticals/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/tarsus-pharmaceuticals/tarsus_pharmaceuticals_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Tarsus Pharmaceuticals Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Horizon (Amgen)'s drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/horizon/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Horizon (Amgen)'s key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Horizon (Amgen)'s portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Horizon (Amgen)'s investment appetite for this drug - Is Horizon (Amgen) actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Horizon (Amgen) need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/horizon/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/horizon/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/horizon/horizon_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Horizon (Amgen) Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Biomarin's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/biomarin/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Biomarin's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Biomarin's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Biomarin's investment appetite for this drug - Is Biomarin actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Biomarin need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/biomarin/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/biomarin/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/biomarin/biomarin_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Biomarin Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Jazz Pharmaceuticals's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/jazz-pharmaceuticals/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Jazz Pharmaceuticals's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Jazz Pharmaceuticals's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Jazz Pharmaceuticals's investment appetite for this drug - Is Jazz Pharmaceuticals actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Jazz Pharmaceuticals need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/jazz-pharmaceuticals/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/jazz-pharmaceuticals/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/jazz-pharmaceuticals/jazz_pharmaceuticals_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Jazz Pharmaceuticals Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Alexion (AstraZeneca)'s drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/alexion/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Alexion (AstraZeneca)'s key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Alexion (AstraZeneca)'s portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Alexion (AstraZeneca)'s investment appetite for this drug - Is Alexion (AstraZeneca) actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Alexion (AstraZeneca) need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/alexion/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/alexion/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/alexion/alexion_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Alexion (AstraZeneca) Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Lundbeck's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/lundbeck/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Lundbeck's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Lundbeck's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Lundbeck's investment appetite for this drug - Is Lundbeck actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Lundbeck need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/lundbeck/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/lundbeck/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/lundbeck/lundbeck_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Lundbeck Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Insmed's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/insmed/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Insmed's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Insmed's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Insmed's investment appetite for this drug - Is Insmed actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Insmed need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/insmed/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/insmed/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/insmed/insmed_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Insmed Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Ultragenyx's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/ultragenyx/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Ultragenyx's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Ultragenyx's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Ultragenyx's investment appetite for this drug - Is Ultragenyx actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Ultragenyx need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/ultragenyx/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/ultragenyx/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/ultragenyx/ultragenyx_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Ultragenyx Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Sobi (Swedish Orphan)'s drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/sobi/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Sobi (Swedish Orphan)'s key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Sobi (Swedish Orphan)'s portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Sobi (Swedish Orphan)'s investment appetite for this drug - Is Sobi (Swedish Orphan) actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Sobi (Swedish Orphan) need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/sobi/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/sobi/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/sobi/sobi_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Sobi (Swedish Orphan) Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Idorsia's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/idorsia/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Idorsia's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Idorsia's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Idorsia's investment appetite for this drug - Is Idorsia actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Idorsia need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/idorsia/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/idorsia/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/idorsia/idorsia_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Idorsia Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Arvinas's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/arvinas/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Arvinas's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Arvinas's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Arvinas's investment appetite for this drug - Is Arvinas actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Arvinas need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/arvinas/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/arvinas/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/arvinas/arvinas_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Arvinas Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Moderna's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/moderna/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Moderna's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Moderna's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Moderna's investment appetite for this drug - Is Moderna actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Moderna need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/moderna/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/moderna/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/moderna/moderna_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Moderna Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Viridian Therapeutics's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/viridian-therapeutics/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Viridian Therapeutics's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Viridian Therapeutics's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Viridian Therapeutics's investment appetite for this drug - Is Viridian Therapeutics actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Viridian Therapeutics need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/viridian-therapeutics/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/viridian-therapeutics/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/viridian-therapeutics/viridian_therapeutics_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Viridian Therapeutics Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Annexon Biosciences's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/annexon-biosciences/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Annexon Biosciences's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Annexon Biosciences's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Annexon Biosciences's investment appetite for this drug - Is Annexon Biosciences actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Annexon Biosciences need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/annexon-biosciences/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/annexon-biosciences/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/annexon-biosciences/annexon_biosciences_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Annexon Biosciences Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Ascendis Pharma's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/ascendis-pharma/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Ascendis Pharma's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Ascendis Pharma's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Ascendis Pharma's investment appetite for this drug - Is Ascendis Pharma actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Ascendis Pharma need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/ascendis-pharma/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/ascendis-pharma/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/ascendis-pharma/ascendis_pharma_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Ascendis Pharma Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Neurocrine Biosciences's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/neurocrine-biosciences/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Neurocrine Biosciences's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Neurocrine Biosciences's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Neurocrine Biosciences's investment appetite for this drug - Is Neurocrine Biosciences actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Neurocrine Biosciences need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/neurocrine-biosciences/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/neurocrine-biosciences/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/neurocrine-biosciences/neurocrine_biosciences_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Neurocrine Biosciences Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Ionis Pharmaceuticals's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/ionis-pharmaceuticals/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Ionis Pharmaceuticals's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Ionis Pharmaceuticals's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Ionis Pharmaceuticals's investment appetite for this drug - Is Ionis Pharmaceuticals actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Ionis Pharmaceuticals need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/ionis-pharmaceuticals/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/ionis-pharmaceuticals/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/ionis-pharmaceuticals/ionis_pharmaceuticals_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Ionis Pharmaceuticals Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Argenx's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/argenx/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Argenx's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Argenx's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Argenx's investment appetite for this drug - Is Argenx actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Argenx need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/argenx/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/argenx/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/argenx/argenx_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Argenx Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

Create an Ada Patient Finder suitability analysis for Merck & Co's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/merck-co/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Merck & Co's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Merck & Co's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Merck & Co's investment appetite for this drug - Is Merck & Co actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Merck & Co need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/merck-co/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/merck-co/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/merck-co/merck_co_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Merck & Co Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

No verdict file found

Create an Ada Patient Finder suitability analysis for Johnson & Johnson's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/johnson-johnson/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Johnson & Johnson's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Johnson & Johnson's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Johnson & Johnson's investment appetite for this drug - Is Johnson & Johnson actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Johnson & Johnson need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/johnson-johnson/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/johnson-johnson/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/johnson-johnson/johnson_johnson_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Johnson & Johnson Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

No verdict file found

Create an Ada Patient Finder suitability analysis for AbbVie's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/abbvie/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify AbbVie's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in AbbVie's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - AbbVie's investment appetite for this drug - Is AbbVie actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does AbbVie need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/abbvie/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/abbvie/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/abbvie/abbvie_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "AbbVie Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

No verdict file found

Create an Ada Patient Finder suitability analysis for Eli Lilly's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/eli-lilly/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Eli Lilly's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Eli Lilly's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Eli Lilly's investment appetite for this drug - Is Eli Lilly actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Eli Lilly need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/eli-lilly/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/eli-lilly/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/eli-lilly/eli_lilly_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Eli Lilly Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

No verdict file found

Create an Ada Patient Finder suitability analysis for Pfizer's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/pfizer/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Pfizer's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Pfizer's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Pfizer's investment appetite for this drug - Is Pfizer actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Pfizer need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/pfizer/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/pfizer/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/pfizer/pfizer_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Pfizer Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

No verdict file found

Create an Ada Patient Finder suitability analysis for Novo Nordisk's drug portfolio using the v4 format. ## IMPORTANT: Read the deep dive first Read ~/clawd/n8n_outputs/novo-nordisk/research_report.md first to get the full drug portfolio. If that file doesn't exist yet, do your own research to identify Novo Nordisk's key drugs. ## Ada Patient Finder Business Model Ada finds undiagnosed patients and navigates them to care. Two product lines: 1. In-Market Finder: patients for drugs already on market 2. Trial Finder: patients for clinical trial enrollment Revenue model: 8-12% of first-year drug revenue per patient found. Positioning: "market expansion" -- not marketing budget. ## What to Analyze From the deep dive (or your research), identify ALL drugs in Novo Nordisk's portfolio. Analyze each using the v4 Section A-D format below. Focus especially on: - Rare disease drugs (highest undiagnosed rates, highest per-patient value) - Specialty drugs with diagnostic delays - Skip mass-market generics and OTC products (mark as NO) ## v4 Report Format (for EACH drug) ### SECTION A -- Market Numbers For EACH market (USA, DACH, Rest of World): 1. Total condition prevalence (show math, cite sources) 2. Undiagnosed patients (underdiagnosis rate x prevalence) 3. DRUG-ADDRESSABLE undiagnosed (CRITICAL: narrow from total undiagnosed to those eligible for THIS specific drug -- filter by indication, line of therapy, severity, age, contraindications. This is NOT the same as total undiagnosed. Show the funnel.) 4. Revenue per patient per year: - WAC (Wholesale Acquisition Cost) - Net revenue per patient after rebates (estimate gross-to-net discount) - Patient Finder fee at 8-12%: revenue to Ada per patient found 5. Annual revenue (latest FY, by region if available) 6. Peak revenue (analyst estimates or derived) 7. Patent expiry / exclusivity dates (US and EU separately) 8. Top 3 competitors with market share ### SECTION B -- Clinical & Diagnostic Profile - Symptoms (what patients experience) - Diagnostic delay (average time to diagnosis) - Common misdiagnoses - Who diagnoses (PCP? Specialist? What triggers referral?) - Can Ada's symptom assessment identify this condition? - Treatment duration (chronic vs acute) - First-line or second-line? ### SECTION C -- Commercial & Strategic Signals - Launch timing and revenue trajectory - Earnings language about patient finding/diagnosis - Competitive pressure - Novo Nordisk's investment appetite for this drug - Is Novo Nordisk actively looking for patients? ### SECTION D -- Patient Finder Opportunity Assessment - Economic opportunity per market (USA/DACH/ROW): - Drug-addressable undiagnosed x net revenue per patient x 8-12% = Ada revenue opportunity - If PF finds 1% of addressable: $X per year - If PF finds 5% of addressable: $X per year - Ada surface ability: Can Ada's symptom checker realistically identify this condition? (1-10) - Company motivation to partner: How badly does Novo Nordisk need help finding patients? (1-10) - Overall Patient Finder fit score: weighted average (1-10) - Tier: 1 (pursue aggressively) / 2 (pursue) / 3 (opportunistic) / NO (not suitable) - Pitch hook: One-liner for the first email ## Quality Rules - Every number needs a source URL - If data unavailable, say "NOT FOUND" -- do NOT fabricate - If sources conflict, show BOTH numbers - Minimum 3 sources per drug for prevalence/revenue claims - Be brutally honest about fit -- if a drug is a bad fit, say NO and explain why ## Output 1. Save to ~/clawd/n8n_outputs/novo-nordisk/patient_finder_analysis.md 2. Save summary to ~/clawd/n8n_outputs/novo-nordisk/patient_finder_summary.json with: drug name, tier, fit score, addressable undiagnosed (USA/DACH/ROW), Ada revenue opportunity 3. Generate HTML at ~/clawd/n8n_outputs/novo-nordisk/novo_nordisk_patient_finder_mar2026.html with: - Georgia serif, navy headers, styled tables - Executive summary table at top: Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity - Footer: "Novo Nordisk Patient Finder Analysis - Ada Cockpit - March 2026" Take your time. Quality over speed.

No verdict file found

Produce a comprehensive, investor-grade deep dive research report on **Eli Lilly**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/eli-lilly/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/eli-lilly/eli_lilly_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Eli Lilly Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Novo Nordisk**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/novo-nordisk/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/novo-nordisk/novo_nordisk_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Novo Nordisk Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Merck & Co**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/merck-co/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/merck-co/merck_co_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Merck & Co Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Pfizer**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/pfizer/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/pfizer/pfizer_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Pfizer Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Johnson & Johnson**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/johnson-johnson/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/johnson-johnson/johnson_johnson_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Johnson & Johnson Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **AbbVie**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/abbvie/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/abbvie/abbvie_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "AbbVie Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **AstraZeneca**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/astrazeneca/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/astrazeneca/astrazeneca_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "AstraZeneca Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Roche**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/roche/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/roche/roche_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Roche Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Novartis**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/novartis/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/novartis/novartis_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Novartis Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Bristol-Myers Squibb**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/bristol-myers-squibb/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/bristol-myers-squibb/bristol_myers_squibb_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Bristol-Myers Squibb Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Sanofi**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/sanofi/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/sanofi/sanofi_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Sanofi Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **GSK**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/gsk/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/gsk/gsk_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "GSK Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Amgen**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/amgen/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/amgen/amgen_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Amgen Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Gilead Sciences**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/gilead-sciences/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/gilead-sciences/gilead_sciences_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Gilead Sciences Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Takeda**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/takeda/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/takeda/takeda_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Takeda Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Boehringer Ingelheim**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/boehringer-ingelheim/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/boehringer-ingelheim/boehringer_ingelheim_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Boehringer Ingelheim Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Regeneron**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/regeneron/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/regeneron/regeneron_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Regeneron Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Bayer**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/bayer/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/bayer/bayer_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Bayer Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Teva**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/teva/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/teva/teva_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Teva Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Vertex Pharmaceuticals**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/vertex-pharmaceuticals/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/vertex-pharmaceuticals/vertex_pharmaceuticals_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Vertex Pharmaceuticals Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Biogen**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/biogen/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/biogen/biogen_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Biogen Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Astellas Pharma**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/astellas-pharma/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/astellas-pharma/astellas_pharma_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Astellas Pharma Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Otsuka**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/otsuka/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/otsuka/otsuka_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Otsuka Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **BridgeBio Pharma**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/bridgebio-pharma/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/bridgebio-pharma/bridgebio_pharma_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "BridgeBio Pharma Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Alnylam Pharmaceuticals**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/alnylam-pharmaceuticals/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/alnylam-pharmaceuticals/alnylam_pharmaceuticals_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Alnylam Pharmaceuticals Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Daiichi Sankyo**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/daiichi-sankyo/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/daiichi-sankyo/daiichi_sankyo_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Daiichi Sankyo Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **UCB**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/ucb/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/ucb/ucb_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "UCB Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Ipsen**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/ipsen/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/ipsen/ipsen_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Ipsen Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Cytokinetics**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/cytokinetics/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/cytokinetics/cytokinetics_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Cytokinetics Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Merck KGaA**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/merck-kgaa/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/merck-kgaa/merck_kgaa_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Merck KGaA Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Galderma**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/galderma/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/galderma/galderma_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Galderma Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Esteve**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/esteve/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/esteve/esteve_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Esteve Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Tarsus Pharmaceuticals**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/tarsus-pharmaceuticals/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/tarsus-pharmaceuticals/tarsus_pharmaceuticals_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Tarsus Pharmaceuticals Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Produce a comprehensive, investor-grade deep dive research report on **Horizon (Amgen)**. ## Report Structure (mandatory sections): ### Executive Summary - Company overview, HQ, founding year, employee count (verify exact figure) - Key financial metrics (latest available fiscal year): revenue, EBITDA, EBITDA margin, net income - Strategic position and growth trajectory - Include 3-year plan or medium-term targets if publicly available - Forward-looking disclaimer: "This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section." ### 1. Company History - Founding, key milestones, major acquisitions, international expansion - Be precise about leadership transitions -- verify which person held which role and when ### 2. Ownership Structure - Public/private, major shareholders, institutional investors - Board composition - Flag any data gaps explicitly ### 3. Leadership / C-Suite - CEO, CFO, key EVPs with verified bios - Include career history and start dates where available - Verify all names against official company website/leadership page ### 4. Drug Portfolio Present as TWO SUMMARY TABLES (one per business unit or therapeutic area) with columns: Product | Revenue (latest FY) | Growth | Patent/Exclusivity Status | Peak Sales Potential | P&L Owner Then detailed write-ups per major product below the tables. ### 5. Top 5 CEO Focus Drugs - Identify the drugs the CEO/leadership emphasizes most in earnings calls and press releases - Revenue, growth trajectory, competitive positioning for each ### 6. P&L Owners - Research ACTUAL names of business unit heads and franchise leads - Include LinkedIn profile URLs where found - If you cannot verify a name, write "Not publicly confirmed" -- do NOT fabricate ### 7. R&D Pipeline - Key pipeline programs with phase, expected readouts, and partnerships - Table format preferred ### 8. Top Geographies - Revenue by region (table format) - Label any estimates as "estimated/derived" ### 9. Competitive Landscape - Key competitors per therapeutic area - Market share where available ### 10. Risks and Challenges - Competition, patent cliffs, regulatory/pricing pressure, FX exposure, pipeline execution risk ### 11. Outlook and Valuation Context - Medium-term targets, market cap or estimated enterprise value - Peer comparison table - Growth narrative tying key products to targets ### 12. Patent/Exclusivity Summary Table Product | Indication | US Exclusivity | EU Exclusivity | Key Risk ## Quality Requirements: - Minimum 3 independent sources per major claim - Cross-reference all financial figures against official sources - Include proper citations throughout (numbered references) - Flag conflicting information explicitly - Minimum 40 sources total - Target length: 60-80KB markdown - Do not fabricate ANY data. If unavailable, say so. - Employee count: include collaborators note if applicable ## Output: 1. Save markdown to ~/clawd/n8n_outputs/horizon/research_report.md 2. Save a summary.json with: report size, source count, key findings 3. Generate styled HTML at ~/clawd/n8n_outputs/horizon/horizon_deep_dive_mar2026.html with: - Georgia serif font, max-width 900px, navy (#0a2540) headers - Tables: collapsed borders, navy header row with white text, alternating row colors - TWO inline SVG charts: revenue mix pie chart by segment + revenue growth trajectory line chart - Executive summary KPI boxes at top - Print-friendly CSS - Full numbered references appendix with clickable links - Footer: "Horizon (Amgen) Deep Dive - Ada Cockpit - March 2026" Use web_search extensively. Cross-reference with multiple sources. Take your time -- quality over speed.

Examine all files, websites, improvements, learnings Daniel has made since he started using OpenClaw, and create a comprehensive, beautiful presentation that explains the purpose of what Daniel has been doing, the learnings, the struggles, the improvements, and everything in detail. Examine additional areas for improvement and explain them. For maximum benefit, what should Daniel be focusing on in the next two weeks, in terms of further building out his tool set, using the existing data sources (internal and external) - which actions would add the most value on the path to getting Ada to 100 million in revenue as quickly as possible? Which actions or tools we could add through OpenClaw would best amplify Daniel's strengths, best cover his weaknesses, and what would be the top 10 highest ROI additions and actions in terms of reaping maximum benefit from OpenClaw, while minimizing wasted time on fixing errors, broken configs, restarting gateways. Come up with a detailed analysis of what has happened so far and what Daniel should be doing next. Publish this in a comprehensive, beautiful format. Compare to best practices and most spectacular success stories on x (use the Grok skill for this if needed). The output should be something spectacular.

No verdict file found

Deeply research, in detail, the entire drug portfolio of Recordati. Revenue per drug per geography, patent lifetime, revenue trend (growing/stale/shrinking) by geography. Name the top 5 focus drugs for the current CEO, based on recent earnings calls, public statements or press releases. Give me the company history, current shareholder structure, biographies of CEO and key management team members. Identify all P&L owners for the top 5 drugs. Analyze and show, in detail, current R&D pipeline - any upcoming significant launches? Show top 5 geographies by revenue and growth trends. Show top 3 competitors with market share for each of the top 5 focus drugs, by geography. Feel free to use the Grok skill for research on x, the Exa skill, the perplexity skill. After reading your report, I want to know Recordati better than 90% of their employees do.

No verdict file found

Draft a response email from Daniel Nathrath (CEO, Ada Health) to Michael Kickuth (GM DACH, Recordati Rare Diseases) who is requesting a meeting about Patient Detection for Cushing Disease. Key context: - Michael spoke with Georg Thies (SVP Global TA Head Endo) who is interested in learning more - They propose March 26 or 27 afternoon for a meeting - They want: (1) Ada Health company presentation, (2) Ada user numbers in US/Germany/Europe, (3) Closed-loop approach for Cushing Disease based on prior Pfizer/Bayer collaborations -- how suspected patients get referred to expert centers or telehealth (Teleclinic DE, Teladoc/MDLive US) with diagnosis/therapy tracking for Isturisa - Recordati markets Isturisa (osilodrostat) for Cushing Disease - High-value rare disease opportunity -- exactly the undiagnosed patient population Ada Patient Finder targets - Tone: warm, professional, in German, enthusiastic - Suggest specific time slots March 26-27 afternoon CET, confirm presentation will be sent ahead - Keep concise and CEO-level Save output to ~/clawd/n8n_outputs/task-<id>/recordati_kickuth_response.md

No verdict file found

Evaluate Galderma's portfolio for its potential for an Ada Patient Finder deal. Research their key drugs, therapeutic areas, pipeline, recent launches, and commercial strategy. Identify which products would benefit most from finding undiagnosed patients. Assess fit with Ada Patient Finder's model (8-12% of first-year drug revenue per patient found, market expansion positioning). Write a concise evaluation with a recommendation. Save output to ~/clawd/n8n_outputs/task-<id>/galderma_evaluation.md

No verdict file found

Create a forwardable email to Richard Francis, CEO of Teva Pharmaceutical, to introduce Ada Patient Finder and get a meeting. The email should: (1) be concise and executive-level, (2) explain Ada Patient Finder briefly -- finds undiagnosed patients and navigates them to care, revenue model is 8-12% of first-year drug revenue per patient found, (3) position as market expansion not marketing budget, (4) include a clear ask for a 30-minute meeting, (5) be written in a tone appropriate for a CEO-to-CEO introduction from Daniel Nathrath CEO of Ada Health. Save the output to ~/clawd/n8n_outputs/task-EMAIL-TEVA/

{"ok":true,"runId":"00427244-c8ae-4189-86ba-42d47801daf3"}

Create a meeting agenda for Daniel Nathrath, Yury Rozenman, and Randal Whitmore in Basel to plan pharma outreach. Two parts: (1) Review Yury outreach list (13 companies: Eli Lilly/Zepbound, Chiesi/Trimbow, GSK/Treelgy+Nucala+Exdensur, AZ/Eohilia+Breztri, Sanofi/Dupixent, Daiichi Sankyo/Enhertu, Eisai/Dayvigo, Merck KGaA/Pimicotinib, Boehringer/Ofev, Novartis/Fabhalta, Resmed/Airsense, Phillips/Respironics). (2) Create Daniel Ada PURSUE list outreach targets -- cross-reference ~/clawd/dashboard/research/ company analyses with the Ada Patient Finder pipeline to identify which PURSUE list companies Daniel should personally target, separate from Yury list. Output: meeting agenda document with both lists side by side, overlap analysis, and proposed division of outreach responsibilities. Save to ~/clawd/chief_of_staff/meeting_prep/basel_outreach_planning.html and ~/clawd/dashboard/meeting_prep/basel_outreach_planning.html

Research whether Galderma has any drugs suitable for the Ada AI Patient Finder Platform. Use the multi-model research protocol: (1) Spawn 4 independent research agents (Opus, Gemini, Grok, GPT) each researching Galderma independently - their drug portfolio, pipeline, conditions treated, undiagnosed patient populations, symptom-based assessment fit, recently launched drugs needing market expansion. (2) Spawn a fact-checker agent that cross-references all 4 outputs against SEC filings, FDA databases, and published sources. (3) Run an arbitration step that reconciles conflicting findings, picks median estimates, and produces the final report. Output format should match existing target analyses in ~/clawd/dashboard/research/. Save to ~/clawd/dashboard/research/galderma/galderma_patient_finder_analysis.html